American Academy

10xBio Announces Data from Interim Analysis of Phase 2b Clinical Trial Showing Superior Efficacy of Novel Drug for Submental Body Contouring

Retrieved on: 
Monday, March 11, 2024
CSFS, PSFS, Biotechnology, Elective surgery, Bruise, Patient, SAN, Abdomen, American Academy, MD, Clinician, Clinical trial, American Academy of Dermatology, Erythema, ITT, FAAD, Pain, AAD, FDA, Organic acid, Edema, Annual general meeting, Pharmaceutical industry

SAN DIEGO, March 11, 2024 /PRNewswire/ -- 10xBio, LLC, a biotechnology company that focuses on new uses for existing therapies and technologies, announced today promising initial clinical trial results on its novel injectable drug for submental body contouring, 10XB101. An innovative alternative to other fat removal options, 10XB101 provides superior efficacy, fewer side effects, enhanced patient tolerability and shorter treatment intervals.

Key Points: 
  • SAN DIEGO, March 11, 2024 /PRNewswire/ -- 10xBio , LLC, a biotechnology company that focuses on new uses for existing therapies and technologies, announced today promising initial clinical trial results on its novel injectable drug for submental body contouring, 10XB101.
  • An innovative alternative to other fat removal options, 10XB101 provides superior efficacy, fewer side effects, enhanced patient tolerability and shorter treatment intervals.
  • "10XB101 has the appropriate product-market fit to capture the tremendous opportunity for submental contouring.
  • In addition, its attributes hold promise for potential expansion to other body contouring applications, such as treatment of the abdomen and flanks."

HealthyChildren.org Celebrates the Arrival of Spring by Hosting a 7-Day Sweepstakes Event

Retrieved on: 
Monday, March 11, 2024
AAP, American Academy of Pediatrics, Parent, American Academy

ITASCA, Ill., March 11, 2024 /PRNewswire-PRWeb/ -- HealthyChildren.org, the official American Academy of Pediatrics (AAP) website for parents, celebrates the arrival of spring by giving away seven $250 gift cards in the site's 2024 Spring Sweepstakes event.

Key Points: 
  • HealthyChildren.org, the official American Academy of Pediatrics (AAP) website for parents, celebrates the arrival of spring by giving away seven $250 gift cards in the site's Spring 2024 Sweepstakes event.
  • The event begins on April 1, 2024, and ends on April 7, 2024.
  • ITASCA, Ill., March 11, 2024 /PRNewswire-PRWeb/ -- HealthyChildren.org, the official American Academy of Pediatrics (AAP) website for parents, celebrates the arrival of spring by giving away seven $250 gift cards in the site's 2024 Spring Sweepstakes event.
  • Registered users of HealthyChildren.org may enter once each day during the event which runs April 1 through April 7, 2024.

More than two-thirds of people with atopic dermatitis and skin of color experienced skin improvement in a first-of-its-kind lebrikizumab study

Retrieved on: 
Sunday, March 10, 2024
Diagnosis, Pigment, LLY, Weill Cornell Medicine, Atopic dermatitis, Health equity, Alaska Natives, Patient, Education, PDCA, Advocate, Diversity, Adherence, Immunology, Research, American Academy, Human, Weill Cornell Medical Center, Dermatitis, African, Skin, Safety, Lilly, Eli Lilly and Company, AAD, Health, IGA, Almirall, Pharmaceutical industry

In this study, treatment with lebrikizumab, an investigational medicine, showed improvement in skin clearance and itch relief.

Key Points: 
  • In this study, treatment with lebrikizumab, an investigational medicine, showed improvement in skin clearance and itch relief.
  • These late-breaking results from a Phase 3 study are being presented today at the American Academy of Dermatology (AAD) Annual Meeting.
  • "People with skin of color are disproportionately affected by atopic dermatitis, often experiencing more severe symptoms, a delay in diagnosis and a lengthier timeframe to find appropriate treatment.
  • "With these initial results, Lilly is taking a step toward investigating the needs of people with skin of color affected by atopic dermatitis."

Online child safety laws could help or hurt – 2 pediatricians explain what’s likely to work and what isn’t

Retrieved on: 
Friday, April 5, 2024
Online, Element, Surgeon, Pediatrics, Friends, Legislation, Algorithm, Face, Q&A, Federation, Risk, Social media, Research, Bullying, Mental health, Policy, Child, American Academy, Adolescence, Safety, Self-harm, Privacy, Government, Parent, Work, Toy

We want to protect them as children and yet launch them into adulthood.

Key Points: 
  • We want to protect them as children and yet launch them into adulthood.
  • Adolescents face risks from testing out independence, navigating peer relationships, developing an identity and making mistakes in these processes.
  • We are pediatricians who study child online behavior, and we are co-directors of the American Academy of Pediatrics Center of Excellence on Social Media and Youth Mental Health.

Ideal legislation

  • Methods for stopping online child sexual exploitation are not adequate, and elements of proposed legislation could help by limiting who can contact teens outside of their known social circles.
  • Another helpful element of child online safety legislation is requiring better access to and control over platform settings.
  • It also is incompatible with the adolescent development ideal of exploration – teens are supposed to test things out, push boundaries and change.
  • Legislation could also require technology companies to take user-reported problems more seriously.
  • Legislation could also focus on limiting the impact of misinformation.

Legislation that would be harmful

  • This restrictive approach would limit access to safe places for many young people and exclude teens who are in unsupportive family settings.
  • These approaches also put the burden on parents to be gatekeepers for every decision about platform access, which has the potential to increase family conflict.
  • Age restrictions may serve to distract from making sure platforms are following guidelines and best practices for all ages.

Limits of legislation

  • There are numerous other critical areas of work, including bullying, mental health and parent burnout that need separate consideration.
  • But policy alone is not likely to solve all of these complex, intertwined issues that intersect in the digital world.

Moving forward

  • The Center of Excellence on Social Media and Youth Mental Health seeks to provide those resources through a Q&A portal, ongoing learning opportunities and resources.
  • Many teens report that parents’ social media use distracts from parent-child interaction and that adult social media use negatively affects them.
  • Dr. Moreno's research team has received funding from Pivotal Ventures to support a research program.
  • She has been paid as an expert witness by the State of California in the matter of Netchoice v. Bonta.
  • The views expressed in this article are Radesky's own and do not necessarily reflect those of the University of Michigan.

Latest data of InnoCare's ICP-332 for the Treatment of Atopic Dermatitis Presented at LBA Session of 2024 AAD

Retrieved on: 
Wednesday, March 13, 2024
High, Safety, HKEX, AAD, IGA, Patient, TYK2, Trial of the century, NRS, American Academy, Pharmaceutical industry

75 eligible AD patients were randomized into three groups: once daily oral ICP-332 80 mg, once daily oral 120 mg, and placebo respectively.

Key Points: 
  • 75 eligible AD patients were randomized into three groups: once daily oral ICP-332 80 mg, once daily oral 120 mg, and placebo respectively.
  • ICP-332 demonstrated a rapid response, with the NRS score from baseline in the two treatment groups showing statistically significant improvement on day 2.
  • With the improvement of pruritus, the quality of life of subjects in the two treatment groups was significantly elevated.
  • The 2024 AAD Annual Meeting is held from March 8 to 12 in San Diego, California, USA.

Leading the Charge: Anmy Mayfield Takes the Reins at WGU's Leavitt School of Health College of Nursing

Retrieved on: 
Monday, March 11, 2024
Refugee, Nursing, Student, College, AACN, Nurse practitioner, Education, Dream, Mentorship, Parent, Family, University, Faculty, LSH, WGU, Medical missions, Patient, Knowledge, Workforce, Community, Nephrology, American Academy

Mayfield has been with WGU for more than five years and is a champion for equity, access, and nontraditional pathways to opportunity.

Key Points: 
  • Mayfield has been with WGU for more than five years and is a champion for equity, access, and nontraditional pathways to opportunity.
  • With her team, she has led the launch and expansion of various innovative nursing programs at the university, including master’s degrees as well as postbaccalaureate and post-master’s certificates in nursing.
  • “Anmy is one of our key pillars at LSH and I feel thrilled to welcome her in the new position.
  • Her expertise in nursing, education, and equity is invaluable to the College of Nursing,” said LSH Senior Vice President and Executive Dean, Keith Smith.

Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting

Retrieved on: 
Monday, March 11, 2024
American Academy of Dermatology, Microbiota, Marketing, FDA, U.S. FDA, Skin, Forehead, Entrepreneurship, Risk, AAD, Safety, GI, Red, Rosacea, Minocycline, Patient, Clinical trial, Erythema, Vagina, Microbiology, American Academy

SCOTTSDALE, Ariz., March 11, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, announces that data from the Phase 1 clinical trial (DFD-29-CD-006) assessing the impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on the microbial flora of healthy adults were presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting that took place March 8-12, 2024, in San Diego, CA. The clinical trial also assessed the safety and tolerability of the treatment. The data were presented by Srinivas Sidgiddi, M.D., Vice President, Research & Development of Journey Medical. DFD-29 is being developed for the treatment of rosacea in collaboration with Dr. Reddy’s Laboratories Ltd.

Key Points: 
  • The clinical trial also assessed the safety and tolerability of the treatment.
  • The data were presented by Srinivas Sidgiddi, M.D., Vice President, Research & Development of Journey Medical.
  • Microbiological samples were collected from the skin (forehead), stool and vagina at multiple timepoints through the study.
  • Additional information on the DFD-29 Phase 1 clinical trial can be found on ClinicalTrials.gov using the identifier NCT05597462 .

Press Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis

Retrieved on: 
Monday, March 11, 2024
Eosinophil, Fever, Week, Headache, OX40L, Conjunctivitis, Scleroderma, Teaching hospital, Atopic dermatitis, Upper respiratory tract infection, Part, Asthma, TARC, Conference, AAD, Safety, Biomarker, Part Two, Hidradenitis suppurativa, IGA, Patient, Inflammation, Chills, Moa, Serum, American Academy, Pharmaceutical industry

The safety profile was consistent with Part 1 of the study with amlitelimab being well-tolerated and no new safety concerns identified.

Key Points: 
  • The safety profile was consistent with Part 1 of the study with amlitelimab being well-tolerated and no new safety concerns identified.
  • Overall rates of treatment-emergent adverse events (TEAEs) were 69.8% for continued amlitelimab treatment, 71.9% for the amlitelimab withdrawal-arm and 66.7% for placebo.
  • TEAEs more commonly observed included headache (11.6% amlitelimab continuation, 3.9% amlitelimab withdrawal, 6.7% placebo), upper respiratory tract infection (9.3% amlitelimab continuation, 5.5% amlitelimab withdrawal, 20% placebo).
  • Amlitelimab is currently under clinical investigation, and its safety and efficacy have not been evaluated by any regulatory authority.

Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting

Retrieved on: 
Sunday, March 10, 2024
Atopic dermatitis, SAN, AAD, Disease, Week, American Academy

In the study, 39.4% of children treated with roflumilast cream 0.05% achieved a 75% improvement in EASI (EASI-75) at Week 4 compared to 20.6% treated with vehicle (P

Key Points: 
  • In the study, 39.4% of children treated with roflumilast cream 0.05% achieved a 75% improvement in EASI (EASI-75) at Week 4 compared to 20.6% treated with vehicle (P
  • “For the pediatric patient population, tradeoffs between efficacy, tolerability, and safety are critical aspects of atopic dermatitis treatment decisions.
  • The data reinforces the well-established efficacy, safety, and tolerability profile of roflumilast cream in atopic dermatitis across the INTEGUMENT program.
  • “Roflumilast cream 0.05% was also shown to be well-tolerated in young children as demonstrated by both investigator and patient-reported outcomes.

MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day

Retrieved on: 
Sunday, March 10, 2024
Psoriatic arthritis, ACR, Doctor of Philosophy, Adalimumab, Skin, American College, Webcast, Moonlake, HS, Patient, Psoriasis, VELA, MMSc, ARGO, MIRA, EDT, Physician, Inflammation, Safety, Prognosis, Clinical trial, Ankylosing spondylitis, TNF, IL-17A, MDA, American Academy, EMA, Medical college, FDA, Food, Steroid, Prevalence, AAD, Event, Joint, PASI, Hidradenitis suppurativa, PSA, PPP, Disease, Porokeratosis, Medicine, Pharmaceutical industry

In addition, by week 24, over 80% and 60% of patients treated with sonelokimab achieved Psoriasis Area Severity Index (PASI) 90 and 100, respectively.

Key Points: 
  • In addition, by week 24, over 80% and 60% of patients treated with sonelokimab achieved Psoriasis Area Severity Index (PASI) 90 and 100, respectively.
  • Treatment with sonelokimab resulted in unprecedented improvements in composite scores that reflect responses in different domains simultaneously.
  • In all composite scores, sonelokimab showed 16-29 percentage point differences to the reference adalimumab arm, comparatively higher to competitors using the same reference arm.
  • The discontinuation rate of the second part of ARGO remained low at 5%, in line with other sonelokimab trials.